{"doc_id": "32401715", "type of study": "Therapy", "title": "", "abstract": "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.\nEffective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic.\nWe assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.\nThis was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong.\nPatients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group).\nThe primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population.\nThe study is registered with ClinicalTrials.gov, NCT04276688.\nBetween Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group.\nThe median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7).\nThe combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4\u00b737 [95% CI 1\u00b786-10\u00b724], p=0\u00b70010).\nAdverse events included self-limited nausea and diarrhoea with no difference between the two groups.\nOne patient in the control group discontinued lopinavir-ritonavir because of biochemical hepatitis.\nNo patients died during the study.\nEarly triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19.\nFuture clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted.\nThe Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine.\nCopyright \u00a9 2020 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 128}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 142}, {"term": "severe acute respiratory syndrome coronavirus 2 RT-PCR", "negation": "negated", "UMLS": {}, "start": 82, "end": 136}, {"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 212}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Triple combination of interferon beta-1b , lopinavir-ritonavir , and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 128}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 142}], "Intervention": [{"term": "Triple combination of interferon beta-1b , lopinavir-ritonavir , and ribavirin", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 78}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We assessed the efficacy and safety of combined interferon beta-1b , lopinavir-ritonavir , and ribavirin for treating patients with COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combined interferon beta-1b , lopinavir-ritonavir , and ribavirin", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 104}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 24}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 35}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h , ribavirin 400 mg every 12 h , and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination of lopinavir 400 mg and ritonavir 100 mg every 12 h , ribavirin 400 mg every 12 h , and three doses of 8 million international units of interferon beta-1b on alternate days", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 234}, {"term": "lopinavir 400 mg and ritonavir 100 mg every 12 h", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 113}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR , and was done in the intention-to-treat population .", "Evidence Elements": {"Participant": [{"term": "severe acute respiratory syndrome coronavirus 2 RT-PCR", "negation": "negated", "UMLS": {}, "start": 82, "end": 136}], "Intervention": [], "Outcome": [{"term": "time to providing a nasopharyngeal swab negative", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 77}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The study is registered with ClinicalTrials.gov, NCT04276688 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 108}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 150}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "median number of days from symptom onset to start of study treatment", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 72}], "Observation": [{"term": "5 days", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 83}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4\u00b737 [95% CI 1\u00b786-10\u00b724], p=0\u00b70010) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 160}], "Outcome": [{"term": "median time from start of study treatment to negative nasopharyngeal swab", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 123}], "Observation": [{"term": "significantly shorter", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 49}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Adverse events included self-limited nausea and diarrhoea with no difference between the two groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the two groups", "negation": "negated", "UMLS": {}, "start": 77, "end": 99}], "Outcome": [{"term": "Adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "self-limited nausea", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 43}, {"term": "diarrhoea", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 57}], "Observation": [{"term": "no difference", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 76}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "One patient in the control group discontinued lopinavir-ritonavir because of biochemical hepatitis .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "control", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 26}], "Outcome": [{"term": "biochemical hepatitis", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 98}], "Observation": [], "Count": [{"term": "One patient", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11}]}, "Evidence Propositions": [{"Intervention": "control", "Observation": "", "Count": "One patient", "Outcome": "biochemical hepatitis"}]}, {"Section": "FINDINGS", "Text": "No patients died during the study .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "died", "negation": "negated", "UMLS": {}, "start": 12, "end": 16}], "Observation": [], "Count": [{"term": "No patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11}]}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "Early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19 .[SEP]", "Evidence Elements": {"Participant": [{"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 212}], "Intervention": [{"term": "Early triple antiviral therapy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 30}, {"term": "lopinavir-ritonavir alone", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 81}], "Outcome": [{"term": "symptoms", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 105}, {"term": "duration of viral shedding", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 151}, {"term": "hospital stay", "negation": "affirmed", "UMLS": {}, "start": 156, "end": 169}], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 39}, {"term": "superior", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 52}, {"term": "alleviating", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 96}, {"term": "shortening", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 120}], "Count": []}, "Evidence Propositions": [{"Intervention": "Early triple antiviral therapy", "Observation": "shortening", "Outcome": "duration of viral shedding", "Count": ""}, {"Intervention": "Early triple antiviral therapy", "Observation": "shortening", "Outcome": "hospital stay", "Count": ""}]}, {"Section": "INTERPRETATION", "Text": "Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "The Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}